A hippocampal-hypothalamic circuit essential for anxiety-related behavioral avoidance

share:

Brief intro:

  • Author: Jing-Jing Yan, Ai-Xiao Chen, Wen Zhang, Ting He, Xiao-Jing Ding, Zi-Xian Yu, Yan-Li Zhang, Mengge He, Haohong Li, Xiao-Hong Xu
  • Journal: BioRxiv
  • Doi: https://www.doi.org/10.1101/2022.01.17.476545
  • Publication Date: 2022 Jan 18

Products/Services used in the paper

Quotation shows PackGene:AAV- CAG-DIO-GtACR1 (Serotype2/5, titer 5.00 x 10^12 vg/mL) was purchased from PackGene Biotech Co, Guangzhou.

Research Field:CNS

AAV Serotype:AAV2/5

Request Quote

Abstract

Anxiety over perceived threats triggers avoidance behavior, but the underlying neural circuit mechanism remains poorly understood. Taking hints from the deep connection between anxiety and predator defense, we examined the role of the anterior hypothalamic nucleus (AHN), a critical node in the predator defense network, in anxiety-related behaviors. By recording Ca2+ transients in behaving mice, we found that activity of AHN GABAergic (AHNVgat+) neurons showed individually stable increases when animals approached unfamiliar objects in an open field (OF) or explored the open arm of an elevated plus-maze (EPM). Moreover, AHNVgat+ neuron activity foreshadowed behavioral retreats and correlated with object and open-arm avoidance. Crucially, exploration-triggered optogenetic inhibition of AHNVgat+ neurons dramatically reduced avoidance behaviors. Furthermore, retrograde viral tracing identified the ventral subiculum (vSub) of the hippocampal formation as a significant input to AHNVgat+ neurons in driving avoidance behaviors. Thus, the activity of the hippocampal-hypothalamic pathway promotes idiosyncratic anxiety-related behavioral avoidance.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download